Franziskus Hospital Harderberg — Clinical Trial Site

47 Registered trials

20 Currently recruiting

Organisation

Franziskus Hospital Harderberg

Location

Georgsmarienhuette, Germany

Identifier

ORG-100033567

Address

Alte Rothenfelder Strasse 23, Harderberg, 49124, Germany

Departments

-
2602: Internistische Onkologie und Hämatologie
Abteilung für Senologie
Apotheke
Center for Hematology and Oncology
Klinik fuer Thoraxonkologie
Klinik für Thoraxonkologie
Medical oncology
Medizinisches Versorgungszentrum II der Niels Stensen Kliniken
MVZ I der Niels-Stensen-Kliniken Zentrum für Internistische Onkologie und Hämatologie
MVZ II der Niels Stensen Kliniken
MVZ II der Niels Stensen Kliniken - Onkologie u. Hämatologie
MVZ II der Niels Stensen Kliniken - Sektion Thoraxonkologie
MVZ II der Niels-Stensen-Kliniken Zentrum für Internistische Onkologie und Hämatologie
MVZ II Zentrum für Hämatologie und Onkologie, Sektion Thoraxonkologie
MVZ II, Sektion Thoraxonkologie
N/A
Niels-Stensen-Kliniken
Oncology
Oncology and Hematology
Onkologie und Haematologie
Onkologie/Hämatologie
Sektion Thoraxonkologie
Thoracic Oncology
Thoraxonkologie
Zentrum fuer Haematologie und Onkologie
Zentrum fuer Internistische Onkologie und Haematologie
Zentrum für internistische Hämatologie und Onkologie
Zentrum für Internistische Onkologie und Hämatologie der Niels-Stensen-Kliniken"
Zentrum für Internistische Onkologie und Haematologie
Zentrum für Internistische Onkologie und Hämatologie
Zentrum für Onkologie und Hämatologie MVZ II

Clinical trials at this site (47)

Search interface

A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally 5 2023-10-12
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended

2022-502322-41-00 Metastatic breast cancer 5 2023-09-12
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer (… Ended

2023-509260-25-00 Locally Recurrent Inoperable or Metastatic Triple-negat 5 2022-07-12
A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati… Ended

2023-503999-24-00 Patients With Locally Advanced (Stage III), Unresectabl 5 2022-06-01
A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended

2023-509943-28-00 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR 5 2022-05-18
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t… Ended

2024-517965-18-00 Advanced NSCLC with common EGFR-Mutation 4 2021-11-11
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 5 2020-12-04
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung… Ended

2024-511185-37-00 Completely resected stage I or IIA non-squamous non-sma 6 2020-11-03
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 locally advanced (stage III) and not suitable for curat 4 2020-03-30
A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended

2023-506783-14-00 Advanced or Metastatic RET Fusion-Positive Non-Small Ce 5 2020-02-24
A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed … Ended

2022-502658-15-00 Resectable Stage II-IIIB Non-small cell lung cancer 5 2019-09-22
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk… Ended

2024-515769-32-00 HR+/HER2- early breast cancer 5 2019-07-02
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re… Ended

2023-506861-76-00 Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage 5 2018-08-09
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13